Halozyme Therapeutics (HTI) Adopts SEC Rule 10b5-1 Policy

Halozyme Therapeutics, Inc. (Amex: HTI) has adopted a policy that provides for the use of pre-arranged trading plans by persons subject to the company's insider trading policy. All such pre-arranged trading plans must (i) comply with certain guidelines established by Halozyme, including volume limitations, (ii) be approved by a committee consisting of independent directors and the company's Chief Financial Officer and (iii) comply with Rule 10b5-1 established by the Securities and Exchange Commission.

You May Also Be Interested In

• Faber - Greek Exit Good for Markets, India and China a Risk
• SIRIUS XM Radio (SIRI) CEO Karmazin Dumps Nearly 14M Shares
• GameStop (GME) CEO Buys 6,570 Shares

Create E-mail Alert Related Categories

Insider Trades

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter